-
公开(公告)号：EP4085914A1
公开(公告)日：2022-11-09
申请号：EP20909539.7
申请日：2020-12-31
发明人： WU, Qi , DU, Zhenxing , WANG, Jie , WANG, Lin , LU, Weidong , SHAO, Qiyun , FENG, Jun , HE, Feng
IPC分类号： A61K31/519 , C07D471/04 , A61P31/12 , A61P31/16 , A61P31/18 , A61P35/00 , A61P37/00
摘要： The present disclosure relates to a crystal form of a pyridopyrimidine derivative and a preparation method thereof, and specifically relates to the crystal form of the compound of formula (I) and a preparation method thereof. The new crystal form has good physical and chemical properties, thereby facilitating clinical treatments.
-
公开(公告)号：EP4053109A1
公开(公告)日：2022-09-07
申请号：EP20881503.5
申请日：2020-10-30
发明人： ZHOU, Xianqiang , DU, Zhenxing , WANG, Jie , WANG, Lin
IPC分类号： C07D235/04 , A61K31/4184
摘要： An acid addition salt of a RORγ regulator. Specifically relating to the acid addition salt of the compound of formula II. More specifically relating to benzoate, oxalate, methanesulfonate, maleate, hydrobromate, hydrochloride salt, and acetate of the compound of formula II and the benzoate crystal form, benzoate amorphous form, oxalate crystal form, oxalate amorphous form, methanesulfonate amorphous form, maleate B crystal form, maleate C crystal form, maleate D crystal form, hydrobromate I crystal form, hydrochloride salt α crystal form, hydrochloride salt β crystal form, hydrochloride salt γ crystal form, and acetate crystal form of the compound of formula II.
-
公开(公告)号：EP3992211A1
公开(公告)日：2022-05-04
申请号：EP20831939.2
申请日：2020-06-24
发明人： YING, Hua , MAO, Langyong , ZHANG, Ling , GE, Hu , TAO, Weikang
IPC分类号： C07K16/30 , C07K19/00 , C12N15/13 , C12N15/63 , A61K39/395 , A61K47/68 , A61P35/00 , G01N33/50
摘要： Provided is an anti-CEA antibody comprising a heavy chain variable region and a light chain variable region, a drug conjugate thereof, and a composition containing the anti-CEA antibody or the drug conjugate thereof, and an application thereof as a drug.
-
公开(公告)号：EP3991730A1
公开(公告)日：2022-05-04
申请号：EP20831251.2
申请日：2020-06-28
申请人： Shanghai Shengdi Pharmaceutical Co., Ltd , Shanghai Senhui Medicine Co., Ltd. , Jiangsu Hengrui Medicine Co., Ltd.
发明人： HUANG, Jian , ZHU, Lingjian , ZOU, Yang , TANG, Yinggang
IPC分类号： A61K31/438 , C07D471/10 , A61P1/08 , A61P11/06 , A61P11/14 , A61P25/06 , A61P25/22 , A61P25/24
摘要： A compound represented by formula II or a pharmaceutically acceptable salt thereof, and a preparation method therefor. The compound represented by formula II is an antagonist of a neurokinin-1 receptor, can be used for treating diseases related to the neurokinin-1 receptor, and can avoid hemolytic effects of drugs and reduce the side effects of drug administration.
-
公开(公告)号：EP3981787A1
公开(公告)日：2022-04-13
申请号：EP20818627.0
申请日：2020-06-03
发明人： FU, Yayuan , MA, Xiaoli , GE, Hu , TAO, Weikang
IPC分类号： C07K16/22 , C12N15/13 , C12N15/63 , A61K39/395 , G01N33/53 , A61P9/10 , A61P9/12 , A61P19/02 , A61P27/06 , A61P35/00 , A61P1/16 , A61P3/10 , A61P11/00 , A61P13/12 , A61P17/00
摘要： Provided are an anti-CTGF antibody comprising variable regions of a light chain and a heavy chain and a use thereof as a drug. The antibody may be used to prepare drugs for treating CTGF-related diseases or conditions.
-
6.发明公开
公开(公告)号：EP3978498A1
公开(公告)日：2022-04-06
申请号：EP20813761.2
申请日：2020-05-22
发明人： LI, Xin , WANG, Bin , BAI, Dongdong , HE, Feng , TAO, Weikang
IPC分类号： C07D487/04 , A61P35/00 , A61K31/4985
摘要： The present application relates to a substituted fused bicyclic derivative, a preparation method therefor, and an application thereof in medicines. Specifically, the present application relates to a novel substituted fused bicyclic derivative as represented by formula (I), a preparation method therefor, a pharmaceutical composition containing the derivative, an application thereof as a therapeutic agent, in particular, as an ERK inhibitor, and an application thereof in preparation of medicines for treatment and/or prevention of cancer, inflammation, or other proliferative diseases, wherein the definitions of the substituents in formula (I) are the same as those in the description.
-
公开(公告)号：EP3939998A1
公开(公告)日：2022-01-19
申请号：EP19888794.5
申请日：2019-11-29
发明人： YANG, Jianjian , LI, Hao , LIU, Xun , JIANG, Jiahua
IPC分类号： C07K16/28 , A61K39/395 , A61P35/00
摘要： The present invention provides a pharmaceutical composition comprising a CD40 antibody or an antigen-binding fragment thereof and an acetic acid-sodium acetate buffer solution, and a use thereof. The pharmaceutical composition may further contain sugar, a non-ionic surfactant, and other excipients. The pharmaceutical composition of the present invention shows good antibody stability.
-
公开(公告)号：EP3936526A1
公开(公告)日：2022-01-12
申请号：EP20766028.3
申请日：2020-03-05
发明人： GU, Xiaoling , YE, Xin , HU, Bing , GE, Hu , TAO, Weikang
IPC分类号： C07K19/00 , C12N15/62 , A61K39/395 , A61P35/00
摘要： Provided are a bifunctional fusion protein and pharmaceutical use thereof. Specifically, provided are a bifunctional fusion protein comprising an SIRPγ peptide variant and an anti-human PD-L1 antibody, an SIRPγ peptide variant, and pharmaceutical use thereof. The bifunctional fusion protein can specifically bind PD-L1 and CD47 to block the binding of PD-L1 or CD47 to a receptor or ligand thereof. In addition, also provided are preparation and application of the bifunctional fusion protein, and treatment of cancers and immune-related diseases.
-
9.发明公开
公开(公告)号：EP3915993A1
公开(公告)日：2021-12-01
申请号：EP20745058.6
申请日：2020-01-22
发明人： HAN, Long , SHAO, Qiyun , FENG, Jun , HE, Feng , MA, Yahui , ZHAO, Miaomiao , DU, Zhenxing , WANG, Jie
IPC分类号： C07D487/04 , A61K31/4985 , A61P1/16 , A61P31/12 , A61P31/16 , A61P31/18 , A61P31/20 , A61P31/22
摘要： The present invention provides a crystal form of a 1,2,3-triazolo[1,5- a ]pyrazines derivative and a preparation method for the crystal form. Specifically, the present invention provides a crystal form of a compound ( S )- N 5 -(3,4-difluorophenyl)-6-methyl- N 3 -((R)-1,1,1-trifluoropropan-2-yl)-6,7-dihydro-[1,2,3]triazolo[1,5- a ]pyrazine-3,5(4 H )-dimethylformamide and a preparation method for the crystal form. The prepared crystal form has good stability and clinical application value.
-
10.发明公开
公开(公告)号：EP3907218A1
公开(公告)日：2021-11-10
申请号：EP20736089.2
申请日：2020-01-03
发明人： YANG, Fanglong , YU, Nan , CHI, Jiangtao , HE, Feng , TAO, Weikang
IPC分类号： C07D237/22 , C07C235/64 , A61K31/166 , A61K31/50 , A61P25/00 , A61P29/00
摘要： A 6-oxo-1,6-dihydropyridazine derivative, a preparation method therefor and medical use thereof, in particular, a 6-oxo-1,6-dihydropyridazine derivative represented by general formula (I), a preparation method therefor, and a pharmaceutical composition containing the derivative, and use thereof as a Na V inhibitor and use thereof in the preparation of a drug for the treatment and/or prevention of pain and pain-related diseases. Each substituent in general formula (I) is the same as defined in the description.
-
-
-
-
-
-
-
-
-
搜索结果
236 条记录 (耗时 0.026 秒)
